CVR - Coronavirus Vaccines R&D Roadmap

Milestone
5.1.d

Long-term investment

In progress
High priority

Establish commitments for long-term investment for coronavirus vaccine R&D, involving key funders from governments, philanthropy, industry, private investment, multilateral organizations, and other entities. 

Progress Highlights

CEPI has secured investments of >$200 million for development of broadly protective coronavirus vaccines, aimed at strengthening global preparedness against a range of coronavirus threats including spill over of novel pathogens into human populations. Partnerships with international organizations, as well as public and private partners, have enabled sustainable financial support. CEPI announced additional financial commitments for development of MERS vaccines in March 2025.

The Global Health Investment Corporation, a nonprofit organization, has forged multiple investment strategies, including public-private partnerships and use of venture capital investment, to accelerate development and commercialization of vaccines and other technologies that prevent or respond to pandemics and other public health emergencies.  

The EU’s Health Emergency Preparedness Authority (HERA) established the investment program, HERA Invest, that supports R&D of vaccines and other countermeasures for public health preparedness and response.  

In May 2025, the World Health Assembly approved the WHO Pandemic Agreement. Article 18 of the agreement addresses sustained financing and establishes a “Coordinating Financial Mechanism.” The Conference of Parties will serve as the governing body  after the Agreement is formally adopted and in force.